GSTP1 gene methylation and AHR rs2066853 variant predict resistance to first generation somatostatin analogs in patients with acromegaly

What Was Tested

Researchers studied Octreotide in this observational study publication.

Biomarkers of clinical and therapeutic outcome in acromegaly are needed.

Polymorphisms or epigenetic changes of detoxification genes, such as those coding for the aryl hydrocarbon receptor (AHR) and the glutathione-S-transferase-P1 (GSTP1), could have a role in GH secreting pituitary tumors' pathophysiology and clinical expression.

In this study, the researchers assessed the contribution of GSTP1 gene promoter methylation status, per se or in combination with the occurrence of the AHR gene rs2066853 variant, on clinical features and response to somatostatin analogs (SSA) treatment in acromegaly patients.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

The researchers enrolled 77 wild-type AIP gene acromegaly patients, who have been screened for germline AHR rs2066853 variant and GSTP1 gene promoter methylation.

Clinical and biochemical parameters were compared after patients' stratification according to GSTP1 methylation status and the presence of AHR rs2066853.

How the Study Was Run

This is an observational, retrospective study, carried out in the Endocrine Unit of an Italian University Hospital.

The researchers also evaluated the response to SSA treatment in 71 cases.

What Was Measured

PubMed files the paper under topics including Acromegaly, Antineoplastic Agents, Hormonal, Basic Helix-Loop-Helix Proteins, Biomarkers, DNA Methylation, Drug Resistance and Genotype.

The authors tagged it with the keywords AHR, AHR rs2066853, GSTP1, GSTP1 methylation and Pituitary tumor.

What This Means in Plain Language

This is an observational study of Octreotide.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2019 (Journal of endocrinological investigation), a journal based in Italy.

More context: the Octreotide compound page, all human trials.